ReviewCellular oncology (Dordrecht, Netherlands)2015
Long non-coding RNAs in cancer: implications for personalized therapy.
Review in Cellular oncology (Dordrecht, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- The Value of Circulating Circular RNA in Cancer Diagnosis, Monitoring, Prognosis, and Guiding Treatment.Frontiers in oncology · 2021Pooled it
- Prognostic and Clinicopathological Significance of Long Non-coding RNA PANDAR Expression in Cancer Patients: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- LncRCD: A Comprehensive Database for Pan-Cancer Characterization of lncRNAs Related to 12 Regulated Cell Death Types.Computational and structural biotechnology journal · 2026Article
- A migrasome-related LncRNA signatures for predicting prognosis and immunotherapeutic response in colorectal cancer.Scientific reports · 2025Article
- Cuproptosis: a novel therapeutic mechanism in lung cancer.Cancer cell international · 2025Review
- Comprehensive analysis of the LINC01122/TPD52 axis as a predictive biomarker in prostate adenocarcinoma.Scientific reports · 2025Article
- Mi-Lnc70 Regulates the Progression of Murine Pancreatic β-Cell Line and Affects the Synthesis of Insulin and Glucagon.OncoTargets and therapy · 2025Article
- Omics-based molecular classifications empowering in precision oncology.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Gain-Type Aneuploidies Influence the Burden of Selective Long Non-Coding Transcripts in Colorectal Cancer.International journal of molecular sciences · 2024Article
- LncRNA MIR210HG promotes the proliferation, migration, and invasion of lung cancer cells by inhibiting the transcription of SH3GL3.The Kaohsiung journal of medical sciences · 2023Article
- Long Noncoding RNAs in Taxane Resistance of Breast Cancer.International journal of molecular sciences · 2023Review
- Advances in Protozoan Epigenetic Targets and Their Inhibitors for the Development of New Potential Drugs.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A five-cuproptosis-related LncRNA Signature: predicting prognosis, assessing immune function & drug sensitivity in lung squamous cell carcinoma.Journal of Cancer · 2023Article
- rs217727 of lncRNA H19 is Associated with Cervical Cancer Risk in the Chinese Han Population.Pharmacogenomics and personalized medicine · 2023Article
- Comprehensive analysis to construct a novel immune-related prognostic panel in aging-related gastric cancer based on the lncRNA‒miRNA-mRNA ceRNA network.Frontiers in molecular biosciences · 2023Article
- Emerging function and clinical significance of extracellular vesicle noncoding RNAs in lung cancer.Molecular therapy oncolytics · 2022Review
- LINC00885 promotes cervical cancer progression through sponging miR-3150b-3p and upregulating BAZ2A.Biology direct · 2022Article
- Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma.Journal of cellular and molecular medicine · 2022Review
- Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma.BioMed research international · 2022Article
- miR‑4306 inhibits the malignant behaviors of colorectal cancer by regulating lncRNA FoxD2‑AS1.Molecular medicine reports · 2021Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs, pseudogenes and circRNAs) have recently come into light as powerful players in cancer pathogenesis and it is becoming increasingly clear that they have the potential of greatly contributing to the spread and success of personalized cancer medicine. In this concise review, we briefly introduce these three classes of long non-coding RNAs. We then discuss their applications as diagnostic and prognostic biomarkers. Finally, we describe their appeal as targets and as drugs, while pointing out the limitations that still lie ahead of their definitive entry into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.